Analysis highlights alignment in biomarker requirements for diagnosing Alzheimer’s disease, suggesting progress in dementia care.
The 2024 AA and IWG diagnostic criteria for Alzheimer’s disease differ in their classification of asymptomatic individuals. Verberk et al. argue, however, that their shared requirement for biomarker use in diagnosis means they are now largely aligned, marking a pivotal step towards precision medicine in dementia care.
No takes yet. Share an insight, caveat, or question.
Verberk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: